CONTEXT: Administration of chemotherapy to premenopausal @entity1 shortens their reproductive lifespan by depleting nonrenewable oocytes. Preservation of fertility is a priority for many such @entity1 , and identification of @entity1 at risk of @entity249 is therefore important. However, age is the only @entity1 characteristic currently recognized to be predictive of long-term ovarian function after chemotherapy. OBJECTIVE: Our objective was to assess markers of ovarian reserve and age as long-term predictors of ovarian function after chemotherapy. DESIGN AND SETTING: We conducted a prospective, longitudinal study at a university hospital and research institute. @entity1 : @entity1 included @entity1 who were premenopausal at the time of diagnosis of early @entity0 . MAIN OUTCOME MEASURES: Ovarian function was assessed at 5 yr follow-up in relation to pretreatment hormonal and ultrasound markers of ovarian reserve. RESULTS: Forty-two @entity1 received (neo-)adjuvant chemotherapy. Continuing menses 4-5 yr after diagnosis closely reflected ovarian activity as assessed by a range of serum markers, including @entity53 , inhibin B, FSH, and anti-m  llerian hormone ( @entity248 ). Pretreatment serum @entity248 , FSH, antral follicle count, and age predicted late ovarian activity by univariate analysis. However, only @entity248 was predictive in a multivariate logistic regression (odds ratio = 13.0; 95% confidence interval = 2.5-66.7); 0.71 ng/ml gave peak likelihood ratio of 7.0 with 54% sensitivity and 92% specificity. Bone mineral density fell over the 4-5 yr after diagnosis with greater loss in @entity1 with lower ovarian activity. Higher pretreatment @entity248 was associated with lower bone mineral density at both lumbar spine and hip at 5 yr (P < 0.02). CONCLUSION: Measurement of @entity248 at @entity5 diagnosis predicts long-term ovarian function after chemotherapy. Use of this in clinical practice may allow better prediction of chemotherapy-related risk to future fertility.

Pretreatment serum anti-m  llerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early XXXX .

@entity1 :: ('9606', 'Species') :: ['women', 'Patients', 'patient', 'PATIENTS'] @entity249 :: ('MESH:D007246', 'Disease') :: ['infertility'] @entity248 :: ('268', 'Gene') :: ['AMH'] @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer'] @entity53 :: ('MESH:D004958', 'Chemical') :: ['estradiol']
@entity0 :: (MESH:D001943,Disease) :: ['breast cancer']
